J Cancer 2023; 14(6):895-902. doi:10.7150/jca.82801 This issue Cite

Research Paper

The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer

Xiaojing Yang, Zhen Li, Lihua Zhang, Hongling Li, Xinmiao Yang, Yi Sun, Lijun Liu, Jie Fu

Department of Radiation Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Citation:
Yang X, Li Z, Zhang L, Li H, Yang X, Sun Y, Liu L, Fu J. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. J Cancer 2023; 14(6):895-902. doi:10.7150/jca.82801. https://www.jcancer.org/v14p0895.htm
Other styles

File import instruction

Abstract

Graphic abstract

Objective: This study aims to analyze the characteristics and factors that influence acute hematological toxicity (HT) during concurrent chemoradiotherapy (CCRT) for cervical cancer, as well as to provide reference data for clinical practice.

Methods: Patients with FIGO IB1-IIA2 cervical cancer who underwent CCRT from May 2018 to August 2020 were included in this study retrospectively. All patients had received external beam radiation therapy and platinum-based concurrent chemotherapy. HT was assessed according to CTCAE 5.0. The pelvic bone marrow was redrawn on the original CT images and divided into four parts: the whole pelvic bone marrow (WP-BM), iliac bone marrow (IL-BM), lower pelvic bone marrow (LP-BM), and lumbosacral bone marrow (LS-BM). The radiation dose and volume of each part of the pelvic bone marrow were recalculated in a new plan created using the original planning parameters. The corresponding dose-volume histogram (DVH) was generated to obtain the bone marrow volumes receiving 10Gy, 20Gy, 30Gy, 40Gy, 45Gy, and 50Gy.

Results: In 112 patients, the incidences of grade 2 or higher leukopenia, anemia, thrombocytopenia, and neutropenia were 49.1%, 2.7%, 1.8%, and 20.5%, respectively. Leukopenia was linked to LS-V20 (r = -0.310; P = 0.006) and radiotherapy treatment lengths (days) (r = -0.416; P = 0.013). Anemia was associated with WP-V30, WP-V40, WP-V45, WP-V50, IL-V20, IL-V40, ILV45, IL-V50, LP-V30, LP-V40, LP-V45, and LP-V50 (P <0.05). Thrombocytopenia (r = -0.304, P = 0.007) and neutropenia (r = -0.368, P = 0.009) was associated only with the length of radiotherapy treatment (day). Multiple regression analysis showed that only anemia was negatively correlated with WP-V30, IL-V40, and LP-V40 (P <0.05).

Conclusions: Acute HT during CCRT in early-stage high-risk cervical cancer may be related to the duration of radiotherapy and the volume of different radiotherapy doses received at different parts in the pelvic bone marrow.

Keywords: Early-stage high-risk cervical cancer, Concurrent chemoradiotherapy, Acute hematological toxicity, Pelvic bone marrow dose volume


Citation styles

APA
Yang, X., Li, Z., Zhang, L., Li, H., Yang, X., Sun, Y., Liu, L., Fu, J. (2023). The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. Journal of Cancer, 14(6), 895-902. https://doi.org/10.7150/jca.82801.

ACS
Yang, X.; Li, Z.; Zhang, L.; Li, H.; Yang, X.; Sun, Y.; Liu, L.; Fu, J. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. J. Cancer 2023, 14 (6), 895-902. DOI: 10.7150/jca.82801.

NLM
Yang X, Li Z, Zhang L, Li H, Yang X, Sun Y, Liu L, Fu J. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. J Cancer 2023; 14(6):895-902. doi:10.7150/jca.82801. https://www.jcancer.org/v14p0895.htm

CSE
Yang X, Li Z, Zhang L, Li H, Yang X, Sun Y, Liu L, Fu J. 2023. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer. J Cancer. 14(6):895-902.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.